La Jolla Pharmaceutical Company found using ticker (LJPC) have now 3 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 20 and 4 with a mean TP of 10.67. Now with the previous closing price of 4.47 this would imply there is a potential upside of 138.7%. The day 50 moving average is 4.48 and the 200 day moving average is 4.33. The company has a market cap of $120m. Find out more information at: http://lajollapharmaceutical.com
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.